Stockreport

Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy [Yahoo! Fina...

Praxis Precision Medicines, Inc.  (PRAX) 
PDF 71% of elsunersen-treated patients achieved 50% seizure reduction by period 6, with sustained benefit observed in the open-label extension for up to one year 100% of [Read more]